154 related articles for article (PubMed ID: 11585967)
1. Thymidine phosphorylase (TP) activation: convenience through innovation.
Van Cutsem E; Cunningham D; Hoff PM; Maroun J
Oncologist; 2001; 6 Suppl 4():1-2. PubMed ID: 11585967
[No Abstract] [Full Text] [Related]
2. [Doxifluridine for treatment of colorectal cancer].
Nishimura G; Miwa K
Nihon Rinsho; 2003 Sep; 61 Suppl 7():345-8. PubMed ID: 14574909
[No Abstract] [Full Text] [Related]
3. Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside.
Ranieri G; Roccaro AM; Vacca A; Ribatti D
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):171-83. PubMed ID: 18221035
[TBL] [Abstract][Full Text] [Related]
4. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?
Bonotto M; Bozza C; Di Loreto C; Osa EO; Poletto E; Puglisi F
Clin Breast Cancer; 2013 Jun; 13(3):167-72. PubMed ID: 23218471
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Morita T; Matsuzaki A; Tokue A
Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
[TBL] [Abstract][Full Text] [Related]
6. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy.
Nishimura G; Terada I; Kobayashi T; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Kayahara M; Shimizu K; Ohta T; Miwa K
Oncol Rep; 2002; 9(3):479-82. PubMed ID: 11956613
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe.
Ou SH; Holcombe RF
Drugs; 2007; 67(4):611-2. PubMed ID: 17352521
[No Abstract] [Full Text] [Related]
10. X-ACT: an important step on an unfinished journey.
Maughan T
Ann Oncol; 2012 Jul; 23(7):1655-8. PubMed ID: 22517823
[No Abstract] [Full Text] [Related]
11. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Iqbal S; Lenz HJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Koizumi W; Okayasu I; Hyodo I; Sakamoto J; Kojima H;
Anticancer Drugs; 2008 Sep; 19(8):819-24. PubMed ID: 18690094
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
O'Neil BH; McLeod HL
J Clin Oncol; 2006 Sep; 24(25):4051-3. PubMed ID: 16943521
[No Abstract] [Full Text] [Related]
14. [Capecitabine in the treatment of colorectal cancer].
Zeuli M; Pino MS; Cognetti F
Tumori; 2001; 87(1 Suppl 1):S55-6. PubMed ID: 11300027
[No Abstract] [Full Text] [Related]
15. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine in the management of colorectal cancer.
Maroun JA
Expert Rev Anticancer Ther; 2001 Oct; 1(3):327-33. PubMed ID: 12113099
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine in the treatment of colorectal cancer.
Kelly C; Cassidy J
Expert Rev Anticancer Ther; 2007 Jun; 7(6):803-10. PubMed ID: 17555390
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Saif MW; Kang SP; Ledbetter L; Steg A; Diasio R; Johnson M
JOP; 2007 Nov; 8(6):799-805. PubMed ID: 17993734
[TBL] [Abstract][Full Text] [Related]
19. [The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Moiseenko VM; Semenova AI; Orlova RV
Vopr Onkol; 2001; 47(1):112-9. PubMed ID: 11317529
[No Abstract] [Full Text] [Related]
20. Thymidine phosphorylase expression and effect of doxifluridine: a phase II study.
Sadahiro S; Otani Y; Oya K; Ike H; Shimada H; Yamaguchi S; Hiki Y; Fujita H; Mitomi T
Oncol Rep; 2001; 8(4):753-8. PubMed ID: 11410777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
